FDA approves generic version of cancer drug Doxil

Mon Feb 4, 2013 2:09pm EST

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012.

Credit: Reuters/Jason Reed

Related Topics

(Reuters) - Health regulators have approved a generic version of the cancer drug Doxil in a move that could ease a months-long shortage that has threatened the lives of thousands of patients.

The Food and Drug Administration said on Monday it approved a version of Doxil, known generically as doxorubicin HCI liposome injection, that is made by Sun Pharma Global FZE, a subsidiary of India's Sun Pharmaceutical Industries Ltd. It will be available in 20 milligram and 50 milligram vials.

Sun's product is the first generic version of Doxil, which was approved in 1995 and is used to treat ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Doxil is made by Johnson & Johnson.

Doxil fell into short supply after manufacturing problems at an outside contract manufacturer, Ben Venue Laboratories Inc, a unit of German drugmaker Boehringer Ingelheim, suspended operations in November 2011 due to quality control problems.

Last February, the FDA allowed for the temporary importation of Lipodox, which is made by Sun and contains the same active ingredient as Doxil. The agency said it intends to continue allowing the importation of Lipodox until Sun has made enough generic Doxil to meet demand.

Late last month a federal judge approved a consent decree under which Ben Venue must bring its Bedford, Ohio facility into compliance with regulatory requirements or face fines and other penalties.

The FDA said the company had repeatedly violated good manufacturing practices. Recent inspections found that poorly maintained equipment deteriorated to the point that it shed particles into injectable drugs, the FDA said.

President Barack Obama made drug shortages a national priority with an executive order in October, 2011.

(Reporting By Toni Clarke; editing by Carol Bishopric)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
ralphos wrote:
In a civilized society If a drug became in short supply no matter the cause,cost,manufacture,war instantly the generic would become available to FDA for approval.

Feb 04, 2013 5:46pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.